The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-
remitting multiple sclerosis points at the critical involvement of B cells in the disease …

Mounting evidence indicates that infection with Epstein–Barr virus (EBV) has a major role in
the pathogenesis of multiple sclerosis (MS). Defective elimination of EBV‐infected B cells by …

Therapy for relapsing–remitting multiple sclerosis (MS) has advanced dramatically despite
incomplete understanding of the cause of the condition. Current treatment involves inducing …

CD20-positive B-cell depletion is a highly promising treatment for multiple sclerosis (MS),
but the mechanisms underlying therapeutic effects are poorly understood. B cells are …

Summary OTHER ARTICLES PUBLISHED IN THIS MINI-REVIEW SERIES ON B CELL
SUBSETS IN DISEASE Transitional B cells in systemic lupus erythematosus and Sjögren's …

2 are likely to be relevant to the pathogenesis of MS. Importantly, these T-cells reacted to
both latent and lytic EBV antigens, suggesting that latent-lytic EBV cycling boosts T-cell …

The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly
used rodent models of experimental autoimmune encephalomyelitis (EAE) hinders the …

Depletion of CD20+ B cells has been related to reduced clinical activity in relapsing–
remitting multiple sclerosis. The underlying mechanism is not understood, because serum …

2 mononuclear cells (Hoover et al., 2008), which is consistent with the sharp reduction in
relapses and MRI activity observed in trials for MS (Hauser et al., 2017). If anti-CD20 …

Background Multiple sclerosis (MS) is often considered to be a CD4, T cell-mediated
disease. This is largely based on the capacity of CD4 T cells to induce relapsing …